Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluating intravenous TAK-573 in combination therapy for relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TAK-573

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Status: WITHDRAWN